Tg Therapeutics (TGTX) Net Income towards Common Stockholders (2009 - 2026)
Tg Therapeutics (TGTX) recorded Net Income towards Common Stockholders of $7.78 million in Q2 2026, down 72.4% from $28.19 million a year earlier and down 60.7% from the prior quarter.
Powered by 
Analysis
Tg Therapeutics (TGTX) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
On a TTM basis, Tg Therapeutics' Net Income towards Common Stockholders came in at $441.49 million as of Jun 30, 2026, up 630.2% year-over-year; for FY2025, it came in at $447.18 million.
- Across earlier years, Net Income towards Common Stockholders came in at $23.38 million in FY2024 (+84.5%), $12.67 million in FY2023, -$223.81 million in FY2022 and -$348.1 million in FY2021.
- The Q2 2026 figure is the lowest quarterly Net Income towards Common Stockholders since Q1 2025.
- On a year-over-year basis, Net Income towards Common Stockholders rose in two of the last five quarters, with growth averaging 86.1%.
- Per Business Quant, the preceding three quarters came in at $19.78 million (Q1 2026), $23.04 million (Q4 2025) and $390.9 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.07 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 3.12 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 3.86 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.24 Bn |
| 10 | Tg Therapeutics | 9.71 Bn | 8.96 Bn | 217.86 Mn | 55.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 55.46 Mn |
| Jun 30, 2026 | 7.78 Mn |
| Mar 31, 2026 | 19.78 Mn |
| Dec 31, 2025 | 23.04 Mn |
| Sep 30, 2025 | 390.90 Mn |
| Jun 30, 2025 | 28.19 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 23.33 Mn |
| Sep 30, 2024 | 3.88 Mn |
| Jun 30, 2024 | 6.88 Mn |
| Mar 31, 2024 | -10.71 Mn |
| Dec 31, 2023 | -14.42 Mn |
| Sep 30, 2023 | 113.93 Mn |
| Jun 30, 2023 | -47.61 Mn |
| Mar 31, 2023 | -39.23 Mn |
| Dec 31, 2022 | -78.47 Mn |
| Sep 30, 2022 | -35.82 Mn |
| Jun 30, 2022 | -40.51 Mn |
| Mar 31, 2022 | -69.01 Mn |
| Dec 31, 2021 | -93.34 Mn |
API Access
Tg Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=TGTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "TGTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=TGTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();